NUCLEAR MEDICINE & THERANOSTICS FOR MOLECULAR IMAGING & TARGETED THERAPY
Dr Aviral Singh,
Clinical Head of Theranostics and Nuclear Medicine, GenesisCare
Murdoch, Western Australia &
Consultant Nuclear Medicine Physician,
Fiona Stanley Hospital, South Metropolitan Health Service &
Royal Perth Hospital, Perth, Australia
RESEARCHER PROFILE
Filmed in Perth, Australia | May 2026
Dr Aviral Singh is a globally renowned Nuclear Medicine Physician with special interest in Theranostics. He holds a Fellowship from the Royal Australasian College of Physicians (2024), specialist certificates in Nuclear Medicine and Radiation Protection from Germany (2019), an MSc in Nuclear Medicine from King’s College London (2005), and Doctor of Medicine and PG Diploma in Cardiology from Zaporozhye State Medical University, Ukraine.
Dr Singh is based in Perth, Western Australia since 2024 and serves as the Clinical Head of Theranostics and Nuclear Medicine at GenesisCare Australia. He is also a Consultant Nuclear Medicine Physician at Fiona Stanley and Royal Perth Hospitals, in addition to pursuing national and international consulting physician roles as Director at Infinity Theranostics.
His prior roles include fellowships at world-leading ENETS Centres of Excellence including, Zentralklinik Bad Berka, Germany and Royal North Shore Hospital, Australia, and consultant physician positions in nuclear medicine and theranostics in Australia, Germany, and UK, with leadership in clinical research and development, and additional training in intensive care and internal medicine.
Dr Singh has co-authored 50 peer-reviewed papers, contributed a book chapter on Copper-64 radiopharmaceuticals, and holds an h-index of 30. He has delivered over 40 invited lectures for prestigious clinical societies worldwide.
Dr. Singh acts as guest editor and associate editor and peer reviewer for multiple reputed nuclear medicine journals. He is an active researcher in the field of personalised nuclear oncology and is an Investigator for several Phase 1 to 4 clinical trials in the field of Theranostics.
Source: Supplied
You Might also like
-
Novel therapies & next-gen medical devices in cardiovascular & vascular disease management
Professor Shirley Jansen AM is a distinguished vascular and endovascular surgeon whose career spans clinical leadership, academic excellence, and pioneering research. She currently holds the Lawrence-Brown Chair of Vascular Surgery at Curtin University’s School of Population Health and serves as Head of the Department of Vascular Surgery at Sir Charles Gairdner Hospital, a role she has held since 2015. In addition, she is the Director of the Heart & Vascular Research Institute at the Harry Perkins Institute for Medical Research. Her early career was marked by prestigious fellowships, including a British Heart Foundation Research Fellowship (1996), and multiple international travelling fellowships from leading surgical societies and industry sponsors between 2001 and 2002.
-
Systems genetics to determine risk of developing diabetes complications
Professor Morahan invented the term “Systems Genetics” for the science field that examines how genetic variants can affect whole networks of genes and whole systems; there are now several laboratories and institutes of systems genetics around the world. He also developed the next-generation genetic resource, The Gene Mine, the most powerful of its type in the world, used globally in rapid mapping and identification of genes. Collaborators nationally and internationally have tested The Gene Mine for traits and diseases in which they specialise.
-
CASE STUDY Large scale genetic study finds link between Irritable Bowel Syndrome & cardiovascular system
Research published April 2024 in the journal Cellular and Molecular Gastroenterology and Hepatology sheds light on disease mechanisms common to irritable bowel syndrome (IBS) and cardiovascular diseases (CVD).